XXXVIII. Comparison with Action of Methysergide and Psilocybin on Test Subjects
Harold A. Abramson, Anabela P. Rolo
Journal of Asthma Research 1965 DOI: 10.3109/02770906509106904 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Experimental comparison Peer reviewed |
|---|---|
| Population | Non-psychotic test subjects |
| Interventions | LSD-25 psilocybin psilocin methysergide |
| Topics | LSD Mescaline Psilocybin |
| Keywords | Methysergide Psychotomimetic Hallucinogen Pharmacology |
| Citations | 21 |
| Key findings | Methysergide produces side effects and tolerance, and its effects were compared with LSD-25, psilocybin, and psilocin in over 150 experiments. |
Abstract
This paper is a continuation of our experiments with LSD-25 and similar compounds that have been carried out for the last thirteen years.1 It employs the same technique described previously2 to compare these drugs on non-psychotic test subjects under suitable conditions. The conditions of the experiment are most important because under certain circumstances the experimental milieu produces so much anxiety that the environment may be said to affect the results as much as the drug itself. Of particular importance is the growing use of methysergide (Sansert) in the treatment of migraine. The frequent occurrence of side affects due to Sansert and the apparent development of tolerance to this derivative of d-lysergic acid has led us to explore the effects of methysergide (Sansert) in the same test subjects used in the study of psychotomimetic drugs for the past ten years. The present series of experiments comparing LSD-25, psilocybin, psilocin and methysergide were begun in 1958. This communication will report on more that 150 experiments with these drugs.
Comparable studies
Other experimental studies on psilocybin, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action Healthy human volunteers | 1998 | Experimental study | |
| Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin Participants in controlled laboratory experiments receiving a moderate to high oral... | 2015 | Validation study using pooled data from five laboratory experiments | n = 184 |
| Broadband Cortical Desynchronization Underlies the Human Psychedelic State Healthy human participants | 2013 | Experimental study | |
| Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer Participants with cancer-related psychiatric distress who completed a parent randomized... | 2020 | Long-term within-subjects follow-up analysis | n = 15 |
| Enzymatic Synthesis of Psilocybin | 2017 | Laboratory study |
Citations in the library
Cited by 11
- The pharmacology of psilocybin Addiction Biology October 1, 2002
- The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act Neuropharmacology June 5, 2018
- Harm potential of magic mushroom use: a review. Regulatory toxicology and pharmacology : RTP April 1, 2011
- The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955–2021) and recommendations for the field Neuroscience & Biobehavioral Reviews May 21, 2022
- The therapeutic potential of microdosing psychedelics in depression Therapeutic Advances in Psychopharmacology 2020
and 6 more in the library
Cites 3
- LYSERGIC ACID DIETHYLAMIDE (LSD-25) American Journal of Psychiatry June 1, 1952
- Lysergic Acid Diethylamide (LSD-25): I. Physiological and Perceptual Responses The Journal of Psychology 1955
- Lysergic Acid Diethylamide (Lsd-25): Xv. the Effects Produced By Substitution of a Tap Water Placebo The Journal of Psychology October 1, 1955